20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T16529 | BEBT-908 | PI3Kα inhibitor 1,MDK9521 | PI3K , HDAC |
BEBT-908 (PI3Kα inhibitor 1) is a selective PI3Kα inhibitor (IC50 <0.1 μM). BEBT-908 also inhibits HDAC (0.1 μM≤IC50≤1 μM). | |||
T9312 | PI3Kα Inhibitor 7 | ||
PI3Kα Inhibitor 7 is a useful organic compound for research related to life sciences. The catalog number is T9312 and the CAS number is 1239978-63-2. | |||
T12589 | PI3Kα/mTOR-IN-1 | PI3K , mTOR | |
PI3Kα/mTOR-IN-1 is a potent dual inhibitor of PI3Kα/mTOR. PI3Kα/mTOR-IN-1 shows an IC50 of 7 nM for PI3Kα in a cell assay, and Kis of 12.5 nM and 10.6 nM for mTOR and PI3Kα in a cell free assay , respectively. | |||
T9315 | 2H-Imidazo[4,5-b]pyrazin-2-one, 1,3-dihydro-6-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- | Others | |
2H-Imidazo[4,5-b]pyrazin-2-one, 1,3-dihydro-6-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- is a potent mTOR inhibitor with IC50 of 0.176 μM and >30 μM for mTOR and PI3Kα, respectively. | |||
T6510 | GDC-0349 | RG-7603 | PI3K , mTOR , Autophagy |
GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1. | |||
T8884 | HSMG-1 inhibitor 11j | PI3K , mTOR | |
hSMG-1 inhibitor 11j is a pyrimidine derivative. hSMG-1 inhibitor 11j is a potent and selective inhibitor of hSMG-1, IC50 = 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), ... | |||
T14511 | BAY1082439 | Apoptosis , PI3K | |
BAY1082439, an orally bioavailable, selective inhibitor of PI3Kα/β/δ, demonstrates high efficacy in inhibiting the growth of Pten-null prostate cancer [1][2]. Additionally, BAY1082439 is effective against mutated forms o... | |||
T14214 | AMG 511 | PI3K | |
AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks(Kis of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively). It exhibits anti-tumor activity in mouse glioblastoma xenograft model[1]. AMG... | |||
T6730 | WAY-600 | WAY600 | VEGFR , PI3K , Src , mTOR |
WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308); selective for mTOR than PI3Kα (>100-fold) and PI3Kγ (>500-fold... | |||
T6319 | OSI-027 | ASP4786,OSI027 | DNA-PK , PI3K , mTOR , Autophagy |
OSI-027 (ASP4786) is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ or DNA-PK. Phase 1. | |||
T36083 | DS-7423 | PI3K , mTOR | |
DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity[1][2]. DS-7423 increases TP53 expression, the level of p-TP53 on Ser... | |||
T35527 | PI3Kα-IN-4 | PI3Kα-IN-4 | |
PI3Kα-IN-4 is a potent, selective, and orally active PI3Kα inhibitor, demonstrating an IC50 of 1.8 nM and exhibiting antitumor activity[1]. | |||
T35488 | (S)-PI3Kα-IN-4 | (S)-PI3Kα-IN-4 | |
(S)-PI3Kα-IN-4 is a potent inhibitor of PI3Kα, with an IC50 of 2.3 nM. (S)-PI3Kα-IN-4 shows 38.3-, 4.25-, and 4.93-fold selectivity for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively. (S)-PI3Kα-IN-4 can be used for the... | |||
T61654 | PI3Kα-IN-9 | ||
PI3Kα-IN-9 (compound 27) is a highly specific, orally active, and long-lasting inhibitor of PI3Kα, demonstrating potent inhibitory effects with IC50 values of 4.4, 128, 146, and 153 nM against PI3Kα, PI3Kγ, PI3Kδ, and PI... | |||
T12460 | PI3K/mTOR Inhibitor-1 | PI3K | |
PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual inhibitor of PI3K/mTOR (PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ/mTOR with IC50s of 20/376/204/46/186 nM) | |||
T11544 | HDACs/mTOR Inhibitor 1 | HDAC | |
HDACs/mTOR Inhibitor 1 is a dual HDACs and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies (IC50s: 0.19 nM, 1.8 nM, 1.2 nM, and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα). | |||
T62438 | PI3K/mTOR Inhibitor-9 | ||
PI3K/mTOR Inhibitor-9 (Compound 1) is a potent inhibitor of both mTOR and PI3K, acting on mTOR (IC50: 38 nM), PI3Kα (IC50: 6.6 nM), PI3Kγ (IC50: 6.6 nM) and PI3Kδ (IC50: 0.8 nM). | |||
T36308 | PF-06843195 | ||
PF-06843195 is a selective PI3Kα inhibitor, demonstrating potent activity with an IC50 of 18 nM in Rat1 fibroblasts and Kis for PI3Kα and PI3Kδ less than 0.018 nM and 0.28 nM, respectively, in biochemical kinase assays. ... | |||
T72374 | PI3K/mTOR Inhibitor-12 | PI3K | |
PI3K/mTOR Inhibitor-12, a potent and selective orally active inhibitor, exhibits IC50 values of 0.06 nM for PI3Kα and 3.12 nM for mTOR, indicating significant antitumor activity with reduced liver toxicity [1]. | |||
T81264 | RLY-2608 | PI3K | |
RLY-2608 is a pioneering, mutant-selective allosteric inhibitor of class IA PI3Kα (phosphoinositide 3-kinase alpha) [1]. |